Losartan + Sunitinib in Treatment of Osteosarcoma is a clinical trial for a bone cancer called osteosarcoma. The study is in Phase 1/1b, which means it is early in testing. It aims to find the best dose of two drugs—Losartan and Sunitinib. The first part of the study, Dose Escalation, involves slowly increasing the dose to see how much patients can safely handle. The second part, Dose Expansion, tests if this dose helps treat the cancer.
Key Points:
- Participants need to be available for the entire study and follow procedures.
- They must be over 10 years old with a specific type of osteosarcoma that hasn’t responded to other treatments.
- Patients should not have had major surgery within 14 days of the study start.
People who join this study will help researchers understand if this treatment can work for osteosarcoma. Participants will be closely monitored for safety and effectiveness of the treatment. It's important for potential participants to discuss with their doctor and understand the benefits and risks before enrolling in the study.